|
Asset Classes |
Type |
Quantity | Business Model | Asset Protection |
Transaction Type |
|
Asset Class I |
The Journal 3/3/2020 Views 1,723,051 |
5,742 articles on 3/3/2020
Valuation [$40M] done by Joel on Alex WP Data |
Revenue Potential: Partnership Programs – Subscription/Access fee Legal and Pharma, free for Academia |
Copyright Law |
B2B & B2B & B2C |
|
Asset Class II |
BioMed e-Series https://pharmaceuticalint elligence.com/2019- vista/global-market- penetration-forecast-for- each-volume-in-the-16- volume-biomed-e- series/ |
16 volumes
Valuation [$5M] done by Joel & Aviva |
Revenue Potential: Partnership Programs – Subscription/Access fee Legal and Pharma, free for Academia |
Copyright Law |
B2B & B2B & B2C |
|
Asset Class III |
eProceedings https://pharmaceuticalint elligence.com/2019- vista/e-proceedings-and- tweet-collections-per- conference-2013-2020- viewsdownloads-x-100- real-time-coverage-of- 60-events-by-ala-sjw/ |
60 events Valuation [$1.4M] done by Dr. Williams & Aviva |
Revenue Potential: Partnership Programs – Subscription/Access fee Legal and Pharma, free for Academia |
Copyright Law |
B2B & B2B & B2C |
|
Asset Class IV |
Platform, composition of methods and workflows for the content creation of scientific curations |
TBD |
Customized Platform Infrastructure, Building Tools for new products, venturing to new Disciplines beyond HealthCare,knowhow contracts in new geographies |
Copyright Law and Proprietary Knowhow |
internal and contracts |
|
Asset Classes |
Type | Quantity | Business Model | Asset Protection |
Transaction Type |
|
Asset Class V |
Gallery of Biological Images in use in Articles and Books |
TBD |
Artifacts in the of Content Creation of PRIOR ART |
Copyright upon EMBEDDED
in original curations |
Internal Use – subsets per BioMed e- Series in Medical Specialties |
|
Asset Class VI |
Team of Experts |
BIOs Final Improvement Team (FIT) |
Factor of Content Creation |
Personal Agreement s to become Employment Contracts Post-Exit |
Internal |
|
Asset Class VII |
Royalties on BioMed e- Series:Page downloads, Book borrowings and Book sale |
111,645 page downloads in total on 3/9/2020 |
Current Account Receivables |
Royalties Agreement with KDP @Amazon |
Derivative of Interest in Content (120,000
Pages download in 16 books |
|
Asset Class VIII |
Subscribers to the Website |
2,554 on 3/29/2020 |
Potential Account Receivables |
n/a |
Drivers of Loyalty & Success |
|
Asset Class IX |
INTANGIBLE ASSETS & Intrinsic Value = Good Will |
TBD |
Potential Account Receivables |
Copyright Law |
External e-Reputation |
| Asset Class X |
e-VOICE PODCASTS Audio Library |
TBD |
Potential Account Receivables |
Copyright Law |
B2B & B2B & B2C |
| Asset
Classes |
Type | Quantity | Business Model | Asset Protection | Transaction Type |
|
Asset Classes |
Unique Value Proposition | Key Paying Customers | Key Stakeholders |
Unique Selling Point |
|
Asset Class I |
We create a new level of knowledge that is current and lively on the current issues and based on a discussion of multiple KOL |
Legal, regulatory, Pharma R&D, Non academia, Gov, Journalists, media, Premium audience |
academics, students, science addicts |
Current high level accessible knowledge |
|
Asset Class II |
in depth as of day of publication knowledge collection of topic, background, good as a course or a journal club guide. State of the art, science based, outcome oriented KOL based perspective. |
Legal, regulatory, pharma R&D, non academia, Gov, journalists and media, premium audience |
Universities, Patient advocacy groups, Professional associations, Curriculum developers |
current highly multiple domain specialized accessible knowledge |
|
Asset Class III |
In depth on publication day, knowledge collection of topic, depicts event spirit and highlights with KOL perspective and annotation, scientific documents and historical state of Science |
Global Biotech & Healthcare Conference Organizers + Customers of Asset Class I+II |
Conference Participants, Future Attendees & Participants Missing Conference Sessions |
Real time, On demand, Event Tweet Collections |
|
Asset Class IV |
platform that allow harnessing the state of knowledge to produce a state of the art coverage of eventual or topic based current knowledge products to a specific targeted audience |
New topics, new geographies knowledge community makers, LPBI new products pipeline |
the global KOL community in health, life- sciences and pharma |
unique, easy, proven, state of the art |
| Transaction Type | Unique Value Proposition | Key Paying Customers | Key Stakeholders | Unique Selling Point |
| Asset Class V |
Selection done by Domain Experts for IP creation of original content |
TBD |
e-Readers, Publishers, Future Publishing Academics |
|
|
Asset Class VI |
Group of outcome-oriented KOLs in Health Care & Pharma Industry & Academia expertise |
Human Capital asset |
||
| Asset Class VII |
Global reach |
e-Readers of Science e-Books |
Scientist- contributors on FIT and Past contributors |
|
| Asset Class VIII |
A reach into the top of the line Executives and KOLs in Pharma and Life sciences R&D |
To be segmented and Targeted for Outreach and Outbound Marketing |
Venture Owner |
Top of the line, majority of the Global market leaders in Biotech |
|
Asset Class IX |
Product/Service Quality & Reputation |
Acquirer and Its Customers |
VERACITY SEEKERS and EVIDENCE BASED MEDICINE PROMOTERS | |
|
Asset Class X |
Selection of most prominent Figures to be featured |
Media Licensing Agreements |
PBS, TV Networks |
|
| Transaction Type | Unique Value Proposition | Key Paying Customers | Key Stakeholders | Unique Selling Point |
2012pharmaceutical
Aashir Awan, Phd
Alan F. Kaul, PharmD., MS, MBA, FCCP
alexcrystal6
anamikasarkar
apreconasia
aviralvatsa
David Orchard-Webb, PhD
danutdaagmailcom
Demet Sag, Ph.D., CRA, GCP
Daniel Menzin
Dror Nir
dsmolyar
evelinacohn
Gail S Thornton
Irina Robu
jdpmd
jshertok
kellyperlman
Ed Kislauskis
larryhbern
Madison Davis
marzankhan
megbaker58
ofermar2020
pkandala
Rosalind Codrington, PhD
ritusaxena
Rick Mandahl
sjwilliamspa
stuartlpbi
Dr. Sudipta Saha
tildabarliya
zraviv06
zs22
Leave a Reply